Universal definition of perioperative bleeding in adult cardiac surgery  by Dyke, Cornelius et al.
EXPERT REVIEWUniversal definition of perioperative bleeding in adult cardiac
surgeryCornelius Dyke, MD,a Solomon Aronson, MD,b Wulf Dietrich, MD, PhD,c Axel Hofmann, ME,d,e,f,g
Keyvan Karkouti, MD,h,i Marcel Levi, MD, PhD,j Gavin J. Murphy, MD, FRCS,k Frank W. Sellke, MD,l
Linda Shore-Lesserson, MD,m Christian von Heymann, MD,n and Marco Ranucci, MDoFrom th
ofMe
Anest
Resea
Unive
Denti
Austr
Resea
Socie
Toron
onto,
Unive
cine a
Amst
sity o
Unite
Brow
siolog
Hofst
ology
Germ
sive C
The auth
in Ca
face-t
manu
search
GmbH
meeti
by an
Switz
the m
Disclosu
honor
resear
honor
and N
consu
Ploug
in any
receiv
comp
Blood
1458Objectives: Perioperative bleeding is common among patients undergoing cardiac surgery; however, the
definition of perioperative bleeding is variable and lacks standardization. We propose a universal definition
for perioperative bleeding (UDPB) in adult cardiac surgery in an attempt to precisely describe and quantify
bleeding and to facilitate future investigation into this difficult clinical problem.
Methods: The multidisciplinary International Initiative on Haemostasis Management in Cardiac Surgery
identified a common definition of perioperative bleeding as an unmet need. The functionality and usefulness
of the UDPB for clinical research was then tested using a large single-center, nonselected, cardiac surgical
database.
Results: A multistaged definition for perioperative bleeding was created based on easily measured clinical end
points, including total blood loss from chest tubes within 12 hours, allogeneic blood products transfused, surgi-
cal reexploration including cardiac tamponade, delayed sternal closure, and the need for salvage treatment.e Department of Cardiothoracic Surgery,a University of North Dakota School
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Dyke et al Expert ReviewDepending on these components, bleeding is graded as insignificant, mild, moderate, severe, or massive. When
applied to an established cardiac surgery dataset, the UDPB provided insight into the incidence and outcome of
bleeding after cardiac surgery.
Conclusions: The proposed UDPB in adult cardiac surgery provides a precise classification of bleeding that is
useful in everyday practice as well as in clinical research. Once fully validated, the UDPB may be useful as an
institutional quality measure and serve as an important end point in future cardiac surgical research. (J Thorac
Cardiovasc Surg 2014;147:1458-63)Supplemental material is available online.
Perioperative bleeding in patients undergoing cardiac sur-
gery is common. Bleeding may be insignificant and not
require treatment or may be serious and life threatening.
Bleeding is frequently treated with allogeneic blood prod-
uct transfusion (packed red blood cells [PRBCs], fresh
frozen plasma [FFP], or platelet concentrates [PLT]).
Although transfusion is recognized to adversely affect early
and late outcomes,1-4 it remains common after cardiac
surgery despite improvements in transfusion medicine and
system-based protocols.5-8
Periprocedural bleeding has become an important
outcome measure in cardiology practice and frequently
serves as a component of combined end points in random-
ized clinical trials (RCTs).9-11 Although precise
definitions for complications such as renal failure, acute
myocardial infarction, and neurologic complications after
cardiac surgery exist,12-16 no standardized definition for
perioperative bleeding has been established, making the
interpretation of clinical trials more difficult and
hindering attempts to study patient blood management.
We propose that a more precise definition of perioperative
bleeding based on easily measurable clinical variables
would improve analysis of this clinical problem and be
useful as a measure of clinical quality. A universal
definition of perioperative bleeding (UDPB) in adult
cardiac surgery would standardize nomenclature, improve
outcome definitions, and be useful in future clinical trials.
The UDPB may also serve as a measure for institutional
quality improvement and a tool to propose, test, and
implement solutions to reduce bleeding and transfusion.
MATERIALS AND METHODS
The authors are involved in the International Initiative for Haemostasis
Management in Cardiac Surgery, an international, multidisciplinary collab-
oration with interest and expertise in the perioperative management of
bleeding associated with cardiac surgery, patient blood management, and
transfusion avoidance. The group recently published an editorial document
addressing current areas in which solid data are lacking to guide blood
management in adult cardiac surgery patients.17
The UDPB was conceived and defined through a series of face-to-face
and interpersonal meetings and represents the consensus opinion of the
group (Table E1). The UDPB was tested using a large, clinical, cardiac,The Journal of Thoracic and Carsurgical database (IRCCSPoliclinico SanDonato,Milan, Italy), which pro-
spectively included all patients undergoing cardiac surgery since 2000. A
retrospective analysis of patients who underwent surgery in 2011 was per-
formed in a post hoc analysis of a recently published study18 that was
approved by the local ethics committee with a waiver of written informed
consent. Data routinely included in the database were supplemented with
additional data from patient files as needed. To verify the clinical impact
of this stratification, operative (30-day) mortality rates were analyzed
and statistically compared for between-group differences. Multivariate an-
alyses (linear, logistic regression) were applied to assess determinants of
UDPB class and the impact of this classification on operative mortality.
A computerized statistical package (SPSS 13.0, Chicago, Ill) was used.RESULTS
UDPB
The UDPB is based on 9 events occurring during surgery
or within the first postoperative day: (1) delayed sternal
closure, (2) postoperative chest tube output, (3) PRBC trans-
fusion, (4) FFP transfusion, (5) PLT transfusion, (6) cryopre-
cipitate transfusion, (7) use of factor concentrates, (8) use of
recombinant activated factor VII (rFVIIa), and (9) surgical
reexploration. The UDPB defines 5 perioperative bleeding
classes, which are designed to characterize the severity of
bleeding, regardless of its source. The contribution of each
of these events to the UDPB is presented in Table 1.Rationale
The presence of the worst, single, predefined attribute is
sufficient to place a patient in a particular bleeding class; the
presence of all attributes within a class is not necessary.
Chest tube output or magnitude of transfusion are not the
sole criteria for the classification. This approach is conser-
vative and ensures the capture of significant bleeding
events. For example, early surgical reexploration may limit
total transfusion or total chest tube output, yet our classifi-
cation identifies the patient as experiencing a severe or class
3 bleeding event. We recognize that the decision to reex-
plore is surgeon dependent and subjective, however reex-
ploration is associated with recognized adverse
consequence,19 and the categorization as severe attempts
to reflect this. This worst-parameter principle was applied
throughout the bleeding classification system.
1. Delayed sternal closure
Delayed sternal closure in clinical practice identifies pa-
tients who experience severe, refractory, intraoperativediovascular Surgery c Volume 147, Number 5 1459
Abbreviations and Acronyms
FFP ¼ fresh frozen plasma
PCC ¼ prothrombin complex concentrates
PLT ¼ platelet concentrate
PRBC ¼ packed red blood cells
RCT ¼ randomized clinical trials
UDPB ¼ universal definition for perioperative
bleeding
Expert Review Dyke et albleeding. In the UDPB, delayed sternal closure is defined as
leaving the operating room with an open or packed chest.
2. Chest tube output
Quantification of intraoperative blood loss using sponge
weight is not commonly used in daily practice and therefore
not included as a determinant in the UDPB. Moreover,
bleeding before protamine administration is not commonly
measured either in clinical practice or in RCTs.
Postoperative chest tube output is easily quantifiable,
routinely used in clinical practice, and has been used as
an outcome measurement in clinical trials.20-22
Limitations exist, however; early reexploration for a high
rate of chest tube output may limit total blood loss,
whereas late chest tube output may represent
accumulation of serum as well as blood. We propose
blood loss beginning with chest closure and over the first
12 hours as a measure for the UDPB, because it reflects
early perioperative events and specifically excludes
intraoperative transfusion during cardiopulmonary bypass
to treat preoperative anemia. We recognize that several
definitions of severe bleeding based on the rate of blood
loss exist,23-26 but are variably applied. Clearly defined
cut-off points are included in the UDPB, because they are
easily measureable and offer a standard definition.
3, 4, and 5. Allogeneic blood product transfusion
Transfusion of allogeneic blood products is usually
included in studies that address perioperative bleeding in
cardiac surgery.2,21,22,27,28 Transfusions of blood products
do not directly measure bleeding in cardiac surgery and
transfusion variability is widely acknowledged, however a
link between severity of bleeding and magnitude of blood
transfused exists. Several studies have used the number of
transfusions for empirical and nonstandardized definitions
for severe (major) and massive bleeding.2,28,29
We propose that the number of allogeneic blood products
transfused according to predefined definitions should be
considered for grading of bleeding severity within the
UDPB. Transfusion of PRBCs in the absence of other clin-
ical signs of bleeding is typically triggered by an anemic
state potentially related to preoperative anemia or excessive
hemodilution. In the UDPB, PRBC units should be1460 The Journal of Thoracic and Cardiovascular Surconsidered when accompanied by other signs of periopera-
tive bleeding and should not be considered if used preoper-
atively or intraoperatively to correct preexisting anemia
unrelated to bleeding. Accordingly, for the purposes of
the UDPB, we count transfusions beginning at chest closure
to avoid preoperative or intraoperative transfusion, which
may not reflect blood loss. The same applies to the use of
PLT, cryoprecipitate, or FFP to correct thrombocytopenia
or coagulation factor deficiencies. For instance, administra-
tion of fibrinogen concentrate to correct low preoperative
fibrinogen levels would not considered in the bleeding
classification.
6. The use of cryoprecipitate
The availability and use of cryoprecipitate varies be-
tween different geographic regions, but, when available, is
frequently used to treat ongoing blood loss and coagulop-
athy by supplementing fibrinogen levels. Thus, cryoprecipi-
tate is a relevant marker for significant bleeding in the
UDPB (at least class 2 or moderate). In regions where cry-
oprecipitate is not available and fibrinogen concentrate is
used, a similar class 2 classification would result. Preoper-
ative administration of cryoprecipitate or fibrinogen
concentrate to correct preexisting hypofibrinogenemia
would not factor into the classification according to the
UDPB.
7. The use of factor concentrates
The use of fibrinogen and prothrombin complex (PCC)
concentrates should be considered as a marker for moderate
bleeding in the UDPB when used as therapy after surgery.
We recognize that prophylactic administration of PCC
before surgery is practiced in patients exposed to oral an-
tithrombotics, but the UDPB definition only includes use
during or after the surgical procedure.30 In principle, we
consider factor replenishment with either blood products
or concentrates as a marker for ongoing bleeding due to fac-
tor deficiency. If a coagulopathy is mitigated with the judi-
cious use of a modest dose of factor concentrate, we define
this as moderate or class 2 bleeding. If persistent bleeding
continues, upstaging is ensured by the presence of other at-
tributes in the definition, such as magnitude of PRBCs
transfused, chest tube output, or reexploration (Table 1).
8. The use of rFVIIa
rFVIIa concentrate is used for difficult, refractory, and
life-threatening bleeding.31,32 The use of rFVIIa under
less severe bleeding circumstances should be avoided
because of the potential risk of thromboembolic
complications.33 The lack of specific criteria guiding the
use of rFVIIa is a weakness of this metric; nonetheless,
the use of rFVIIa has evolved to portend the treatment of
massive bleeding when other treatment options have failed,
and is scored accordingly.gery c May 2014
TABLE 1. Bleeding categories according to the UDPB in adult cardiac surgery (if different categories indicate mixed definitions of bleeding, the
worst definition applies)
Bleeding
definition
Sternal closure
delayed
Postoperative chest tube
blood loss within
12 hours (mL)
PRBC
(units)
FFP
(units)
PLT
(units) Cryoprecipitate PCCs rFVIIa
Reexploration/
tamponade
Class 0 (insignificant) No <600 0* 0 0 No No No No
Class 1 (mild) No 601-800 1 0 0 No No No No
Class 2 (moderate) No 801-1000 2-4 2-4 Yes Yes Yes No No
Class 3 (severe) Yes 1001-2000 5-10 5-10 N/A N/A N/A No Yes
Class 4 (massive) N/A >2000 >10 >10 N/A N/A N/A Yes N/A
UDPB, Universal definition for perioperative bleeding; PRBC, packed red blood cells; FFP, fresh frozen plasma; PLT, platelet concentrates; PCCs, prothrombin complex con-
centrates; rFVIIa, recombinant activated factor VII; N/A, not applicable. *Correction of preoperative anemia or hemodilution only; the number of PRBCs used should only be
considered in the UDPB when accompanied by other signs of perioperative bleeding.
Dyke et al Expert Review9. Surgical reexploration
Surgical reexploration is a common rescue technique
when operative techniques or transfusions fail to stop
ongoing blood loss, but is not innocuous and adversely af-
fects outcomes after cardiac surgery.19 Surgical reexplora-
tion can occur early or late, and although the temporal
relation to chest tube blood loss may be variable, we
consider it to always be a significant negative clinical
event.34,35 The incidence of postoperative reexploration is
easily measured and frequently used as a quality
indicator.28,29,35 Surgical reexploration is included in the
UDPB as a measure of severe bleeding.
A postsurgical change in hemoglobin concentration was
considered, but is not a component of the UDPB. Although
decrease in hemoglobin concentration is included as part of
a definition of bleeding for use in nonsurgical cardiovascu-
lar trials,9 hemoglobin changes in the cardiac surgery
setting may not be directly related to bleeding. Significant
decreases in hemoglobin concentration may result in trans-
fusion, which is a component of the definition.FIGURE 1. Bleeding classification according to the UDPB using a test
series (N ¼ 1144).Using the UDPB for Database Queries: A Test Case
The UDPB was used to analyze a nonselected series of
1144 adult patients who underwent cardiac operations at a
single institution during the 2011 calendar year. The type
of cardiac operations performed is summarized in Table E2
and the UDPB distribution is shown in Figure 1. More than
50% of the patient population had insignificant bleeding
and 10% of patients had bleeding categorized as severe
and massive.
The 9 event categories were successful in adjudicating
patients to the appropriate UDPB class, and adjudication
to the UDPB classes was conservative, so that a single attri-
bute was sufficient to upgrade a patient’s bleeding classifi-
cation. Patients were attributed to class 1 or mild bleeding
(n ¼ 170) largely as a result of the number of PRBC units
transfused (n ¼ 97, 57%) and the amount of postoperative
chest drain blood loss (n ¼ 66, 39%), Patients with class 2
or moderate bleeding (n ¼ 274) were principally assignedThe Journal of Thoracic and Caras a result of the number of PRBC units transfused (n ¼
151, 55%), followed by a combination of different events
(n¼ 67, 24%), platelet concentrate use (n¼ 22, 8%), chest
drain blood loss (n¼ 12, 4.4%), FFP use (n¼ 11, 4%), and
delayed sternal closure (n ¼ 10, 4%). Patients in the severe
bleeding class (n ¼ 94) were adjudicated based on the
number of PRBC units administered (n ¼ 49, 52%), fol-
lowed by a combination of events (n ¼ 24, 25%), chest
drain blood loss (n ¼ 15, 16%), surgical revision (n ¼ 4,
4%), and FFP use (n ¼ 2, 2%). Patients who experienced
massive bleeding (n ¼ 18) were adjudicated based on a
combination of events (n ¼ 10, 56%), PRBC transfusion
(n¼ 5, 28%), and administration of rFVIIa as salvage ther-
apy (n ¼ 3, 17%).
The determinants of UDPB class were explored with uni-
variate and multivariate analyses. Factors considered were
the preoperative risk stratification (logistic EuroSCORE
I), plus additional variables not included in the EuroSCORE
(diabetes, preoperative use of low-molecular-weight hepa-
rin, type of operation, preoperative hematocrit, and cardio-
pulmonary bypass duration). Independent predictors of the
UDPB class were EuroSCORE, preoperative hematocrit,
and cardiopulmonary bypass duration (Table 2). Becausediovascular Surgery c Volume 147, Number 5 1461
TABLE 2. Independent predictors of UDPB classification
UDPB class n EuroSCORE score (%) Preoperative hematocrit (%) CPB duration, minutes (SD)
Class 0 (insignificant) 588 4.7 (5.2) 40.0 (4.3) 78.2 (30.6)
Class 1 (mild) 170 5.5 (4.8) 38.2 (3.9) 77.2 (29.1)
Class 2 (moderate) 274 11.1 (12.3) 35.5 (5.1) 99.1 (47.8)
Class 3-4 (severe-massive) 112 13.0 (15.4) 35.5 (6.5) 138.5 (81.4)
P value .001 .001 .001
UDPB, Universal definition for perioperative bleeding; CPB, cardiopulmonary bypass; SD, standard deviation.
Expert Review Dyke et alof the low number of patients in UDPB class 4 (18 patients),
for the purposes of this analysis, UDPB classes 3 (severe)
and 4 (massive) were merged into a single class.UDPB and Operative Mortality
In a further analysis, the operative (30-day) mortality rate
in each of the UDPB classes was explored. Higher classifi-
cation within the UDPB correlated with higher mortality in
the univariate analysis. There were significant differences
between bleeding classes, with a low mortality rate in pa-
tients classified as having irrelevant or mild bleeding, and
significantly higher values in patients experiencing moder-
ate, severe, or massive bleeding. Patients with severe or
massive bleeding had a combined mortality of 22.3%.
These data were adjusted for the potential confounders
previously identified (EuroSCORE, preoperative hemato-
crit, and cardiopulmonary bypass duration) in a multivariate
logistic regression model. Within this model, the UDPB
class remained an independent predictor of operative mor-
tality, with an odds ratio of 2.18 (95% confidence interval,
1.55-3.07; P ¼ .001), corresponding to a relative risk of
operative mortality that doubles with each increase in
UDPB class. Crude and adjusted mortality rates are shown
in Figure 2.FIGURE 2. Mortality according to the UDPB classification scheme using
a test series (N ¼ 1144).DISCUSSION
Excessive bleeding after cardiac surgery remains a com-
plex clinical problem despite significant advances in surgi-
cal technique, anesthetic management, and critical care.
Although there is general agreement that less bleeding is
better and avoidance of transfusion a laudatory goal, all
patients bleed after surgery and it remains unclear at
what point bleeding becomes clinically significant. We
believe that these questions can only be tested with a
more precise definition of bleeding. The UDPB uses mul-
tiple clinically relevant parameters to create a simple 5-
class system that can be applied in everyday practice
and in clinical investigations to classify perioperative
bleeding.
Limitations and some arbitrariness exist with any defini-
tion of bleeding. Chest tube output is a continuous measure-
ment of flow, and we acknowledge that the difference
between 750 and 800 mL of chest tube drainage is probably
irrelevant. This is mitigated by the use of multiple criteria in1462 The Journal of Thoracic and Cardiovascular Suraddition to chest tube output in the UDPB. The UDPB is in-
tended to quantify and define perioperative bleeding, not
transfusion for other reasons or outside the perioperative
period. The UDPB is also not meant to be predictive or iden-
tify risk factors for bleeding, but to define bleeding when it
occurs. It is to be hoped that this definition will serve as a
tool for future investigations and modifications can be ex-
pected based on clinical evidence.
Our test case suggests that the UDPB is useful as a
descriptive tool and may assist in predicting clinical out-
comes. Different classes of bleeding were associated with
different mortality rates after adjustment for the other
relevant confounders. Two thirds of postsurgical bleeding
was insignificant or mild, and mortality among these pa-
tients was low. No differences in mortality were seen be-
tween the insignificant or mild bleeding classes.
Moderate bleeding, however, was associated with a sig-
nificant increase in mortality, and mortality rates
continued to increase dramatically for severe and massive
bleeding. Although the high mortality associated with se-
vere or massive bleeding confirms clinical experience, in
the test case, mild bleeding was truly insignificant, which
suggests that efforts to shift patients from moderate
bleeding to an insignificant or mild bleeding category
seem worthwhile. Other clinical outcomes such as length
of stay in the intensive care unit or ventilation await
future analysis.gery c May 2014
Dyke et al Expert ReviewCONCLUSIONS
Postoperative bleeding in most cardiac surgical patients
does not require transfusion, does not adversely affect hos-
pital course, and is without clinical consequence. Despite
algorithms to identify patients at high risk for bleeding
and consensus guidelines for the prevention of postopera-
tive bleeding, the definition of bleeding in the cardiac surgi-
cal patient is variable. The UDPB precisely defines the
magnitude of perioperative bleeding, and preliminary
investigation suggests that these classes have clinical rele-
vance and may correlate with postoperative mortality. We
propose that the UDPBmay be helpful in defining strategies
and improving implementation of demonstrated protocols
to minimize bleeding and transfusion in cardiac surgical
patients.References
1. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL,
Blackstone EH, Sabik JF III. Morbidity of bleeding after cardiac surgery: is it
blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;
91:1780-90.
2. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E,
McCluskey SA, et al. The independent association of massive blood loss with
mortality in cardiac surgery. Transfusion. 2004;44:1453-62.
3. Surgenor SD, DeFoe GR, Fillinger MP, Likosky DS, Groom RC, Clark C, et al.
Intraoperative red blood cell transfusion during coronary artery bypass graft
surgery increases the risk of postoperative low-output heart failure. Circulation.
2006;114(1 Suppl):I43-8.
4. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery.
Semin Cardiothorac Vasc Anesth. 2004;8:267-81.
5. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac
Cardiovasc Surg. 2011;142:662-7.
6. Loor G, Vivacqua A, Sabik JF III, Li L, Hixson ED, Blackstone EH, Koch CG.
Process improvement in cardiac surgery: development and implementation of a
reoperation for bleeding checklist. J Thorac Cardiovasc Surg. 2013;146:
1028-32.
7. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical
outcomes and transfusion of minimal amounts of blood in the operating room.
Arch Surg. 2012;147:49-55.
8. Spiess BD. Blood transfusion and infection after cardiac surgery. Ann Thorac
Surg. 2013;95:1855-8.
9. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al.
Standardized bleeding definitions for cardiovascular clinical trials. Circulation.
2011;123:2736-47.
10. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of
aspirin dose when used alone or in combination with clopidogrel in patients with
acute coronary syndromes: observations from the Clopidogrel in Unstable angina
to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-7.
11. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI
Study Group. N Engl J Med. 1985;312:932-6.
12. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al.
Definition and evaluation of transient ischemic attack: a scientific statement
for healthcare professionals from the American Heart Association/American
Stroke Association Stroke Council; Council on Cardiovascular Surgery and
Anesthesia; Council on Cardiovascular Radiology and Intervention; Council
on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral
Vascular Disease. The American Academy of Neurology affirms the value of
this statement as an educational tool for neurologists. Stroke. 2009;40:2276-93.
13. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al.
Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38.
14. Englberger L, Suri RM, Li Z, Casey ET, Daly RC, Dearani JA, et al. Clinical
accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute
kidney injury in patients undergoing cardiac surgery. Crit Care. 2011;15:R16.The Journal of Thoracic and Car15. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure -
definition, outcome measures, animal models, fluid therapy and information
technology needs: the Second International Consensus Conference of the Acute
Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-12.
16. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al.
Acute Kidney Injury Network: report of an initiative to improve outcomes in
acute kidney injury. Crit Care. 2007;11:R31.
17. Ranucci M, Aronson S, Dietrich W, Dyke CM, Hofmann A, Karkouti K, et al.
Patient blood management during cardiac surgery: do we have enough evidence
for clinical practice? J Thorac Cardiovasc Surg. 2011;142:249, e1-32.
18. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G. Surgical, Clinical
Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia:
the deadly triad of cardiac surgery. Ann Thorac Surg. 2013;96:478-85.
19. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration
for bleeding is a risk factor for adverse outcomes after cardiac operations.
J Thorac Cardiovasc Surg. 1996;111:1037-46.
20. Christensen MC, Krapf S, Kempel A, von Heymann C. Costs of excessive
postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg. 2009;
138:687-93.
21. Ranucci M, Castelvecchio S, Romitti F, Isgro G, Ballotta A, Conti D. Living
without aprotinin: the results of a 5-year blood saving program in cardiac surgery.
Acta Anaesthesiol Scand. 2009;53:573-80.
22. Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L. Can local application of
Tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized
controlled trial. J Cardiothorac Surg. 2009;4:25.
23. Fergusson DA, Hebert PC,Mazer CD, Fremes S, MacAdams C,Murkin JM, et al.
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
N Engl J Med. 2008;358:2319-31.
24. Herwaldt LA, Swartzendruber SK, Zimmerman MB, Scholz DA, Franklin JA,
Caldarone CA. Hemorrhage after coronary artery bypass graft procedures.
Infect Control Hosp Epidemiol. 2003;24:44-50.
25. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D.
Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery
patients receiving thienopyridines. Ann Thorac Surg. 2011;91:123-9.
26. Diprose P, Herbertson MJ, O’Shaughnessy D, Gill RS. Activated recombinant
factor VII after cardiopulmonary bypass reduces allogeneic transfusion in com-
plex non-coronary cardiac surgery: randomized double-blind placebo-controlled
pilot study. Br J Anaesth. 2005;95:596-602.
27. Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymondos K, Scheinichen D,
et al. Recovery of fibrinogen after administration of fibrinogen concentrate to pa-
tients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth.
2010;104:555-62.
28. Karkouti K, Wijeysundera DN, Beattie WS, Callum JL, Cheng D, Dupuis JY,
et al. Variability and predictability of large-volume red blood cell transfusion
in cardiac surgery: a multicenter study. Transfusion. 2007;47:2081-8.
29. Karkouti K,Wijeysundera DN, Yau TM,McCluskey SA, Tait G, BeattieWS. The
risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth
Analg. 2010;110:21-9.
30. Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M. Fibrinogen
concentrate reduces intraoperative bleeding when used as first-line hemo-
static therapy during major aortic replacement surgery: results from a
randomized, placebo-controlled trial. J Thorac Cardiovasc Surg. 2013;
145(3 Suppl):S178-85.
31. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, et al.
Recombinant activated factor VII for refractory bleeding after cardiac
surgery–a retrospective analysis of safety and efficacy. Crit Care Med. 2005;
33:2241-6.
32. Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, et al.
Comprehensive Canadian review of the off-label use of recombinant activated
factor VII in cardiac surgery. Circulation. 2008;118:331-8.
33. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic
adverse events after use of recombinant human coagulation factor VIIa. JAMA.
2006;295:293-8.
34. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A. Surgical
reexploration after cardiac operations: why a worse outcome? Ann Thorac
Surg. 2008;86:1557-62.
35. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration
for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the
effect of time delay. Ann Thorac Surg. 2004;78:527-34; discussion 34.diovascular Surgery c Volume 147, Number 5 1463
TABLE E1. Literature search strategies
Search Topic, subtopic, and MeSH terms Date No. of hits
1 Blood loss during cardiac surgery (‘‘Cardiac Surgical Procedures’’[Mesh] OR
‘‘Coronary Artery Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR
‘‘Extracorporeal Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh]
OR ‘‘Blood Loss, Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh])
December 5, 2011 865
2 Treatment Outcome (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery
Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal
Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss,
Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Treatment Outcome’’[Mesh]
December 5, 2011 278
3 Blood Transfusion (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery
Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal
Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss,
Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Blood Transfusion’’[Mesh]
December 5, 2011 286
4 Erythrocyte Transfusion (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery
Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal
Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss,
Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Erythrocyte Transfusion’’[Mesh]
December 5, 2011 51
5 Plasma (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery Bypass’’[Mesh]
OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal Circulation’’[Mesh])
AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss, Surgical’’[Mesh]
OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Plasma’’[Mesh]
December 5, 2011 17
6 Platelet Transfusion (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery
Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal
Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss,
Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Platelet Transfusion’’[Mesh]
December 5, 2011 17
7 Factor VIIa (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery Bypass’’[Mesh]
OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal Circulation’’[Mesh]) AND
(‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss, Surgical’’[Mesh] OR ‘‘Hemostasis,
Surgical’’[Mesh]) AND ‘‘Factor VIIa’’[Mesh]
December 5, 2011 51
8 Reoperation (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery Bypass’’[Mesh]
OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal Circulation’’[Mesh]) AND
(‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss, Surgical’’[Mesh] OR ‘‘Hemostasis,
Surgical’’[Mesh]) AND ‘‘Reoperation’’[Mesh]
December 5, 2011 159
9 Cardiac Tamponade (‘‘Cardiac Surgical Procedures’’[Mesh] OR ‘‘Coronary Artery
Bypass’’[Mesh] OR ‘‘Cardiopulmonary Bypass’’[Mesh] OR ‘‘Extracorporeal
Circulation’’[Mesh]) AND (‘‘Postoperative Hemorrhage’’[Mesh] OR ‘‘Blood Loss,
Surgical’’[Mesh] OR ‘‘Hemostasis, Surgical’’[Mesh]) AND ‘‘Cardiac Tamponade’’[Mesh]
December 5, 2011 16
Comprehensive literature searches were performed using the indexed online database MEDLINE/PubMed. Lists of cited literature within relevant articles and the authors’ own
libraries were also screened. Boolean operators and Medical Subject Heading (MeSH) thesaurus keywords were applied as a standardized use of language to unify differences in
terminology into single concepts. Searches were limited to human studies, adults, and published in the last 10 years. Full publications were retrieved based on evaluation of
abstracts that were deemed relevant to the queries posed.
TABLE E2. Type of surgical operation performed in the single-center
patient test series
Operation n (%)
Isolated coronary revascularization 347 (30)
Isolated mitral valve procedure 191 (17)
Isolated aortic valve procedure 188 (16)
Coronary revascularization þ valve procedure 180 (16)
Coronary revascularization þ left ventricle aneurismectomy 39 (3)
Double/triple valve 114 (10)
Ascending aorta/aortic arch procedure 85 (7)
Total 1144 (100)
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